Search

Displaying results 2271 - 2280 of 8575 in total
  1. Drug

    Acetohexamide

    go.drugbank.com/drugs/DB00414
    ApprovedWithdrawn

    Acetohexamide has been discontinued in the US market.

    Products: Dimelor Tablet 1843 500mg
  2. Drug

    Danaparoid

    go.drugbank.com/drugs/DB06754
    ApprovedWithdrawn

    While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer. … The use of Orgaran™ was discontinued in the United States however it is available in several other countries including European countries and Japan.

  3. Drug

    Umifenovir

    go.drugbank.com/drugs/DB13609
    Investigational

    [A191475] It has been in use in Russia for approximately 25 years and in China since 2006. … [A191475,A191412] This dual activity may also confer additional protection against viral resistance, as the development of resistance to umifenovir does not appear to be significant.

  4. Drug

    Tianeptine

    go.drugbank.com/drugs/DB09289
    Investigational

    Currently, tianeptine is approved in France and manufactured and marketed by Laboratories Servier SA; it is also marketed in several other European countries under the trade name “Coaxil” as well as in … Tianeptine was discovered and patented by The French Society of Medical Research in the 1960s [L2946].

  5. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

  6. Drug

    Mezlocillin

    go.drugbank.com/drugs/DB00948
    Approved

    It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.

  7. Drug

    Obecabtagene autoleucel

    go.drugbank.com/drugs/DB17362
    ApprovedInvestigational

    [L52450] Obecabtagene autoleucel was also investigated in other hematological cancers and systemic lupus erythematosus.[A265045] … [A265050] On November 8, 2024, obecabtagene autoleucel was approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

  8. Drug

    Metaxalone

    go.drugbank.com/drugs/DB00660
    ApprovedInvestigational

    Metaxalone is associated with few side effects and is available as a 800 mg scored tablet.

  9. Drug

    H3B-8800

    go.drugbank.com/drugs/DB14017
    Investigational

    H3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551]. … It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting [A32749

  10. Drug

    Aripiprazole lauroxil

    go.drugbank.com/drugs/DB14185
    Approved

    It is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors [A34289]. … On July 2nd, a different formulation of aripiprazole lauroxil marketed as Aristada Initio was FDA-approved for immediate initiation of Aristada at any dose.